| Profile | GDS2987 / GI_11761637-S |
| Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
| Organism | Homo sapiens |
| Sample | Title | Value | Rank |
|---|---|---|---|
| GSM214810 | HMVEC_vehicle_rep1 | 6.6 | 24 |
| GSM215244 | HMVEC_vehicle_rep2 | ||
| GSM215253 | HMVEC_vehicle_rep3 | 11.6 | 37 |
| GSM215254 | HMVEC_atorvastatin_rep1 | 18.5 | 44 |
| GSM215282 | HMVEC_atorvastatin_rep3 | 24.1 | 49 |
| GSM215344 | HMVEC_atorvastatin_rep2 | 34.3 | 60 |
| GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
| GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
| GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 26.9 | 41 |
| GSM215294 | HMVEC_SLx2119_rep1 | 12.6 | 42 |
| GSM215295 | HMVEC_SLx2119_rep2 | 20.2 | 38 |
| GSM215296 | HMVEC_SLx2119_rep3 | ||
| GSM215297 | PASMC_vehicle_rep1 | ||
| GSM215298 | PASMC_vehicle_rep2 | ||
| GSM215310 | PASMC_vehicle_rep3 | 12 | 19 |
| GSM215311 | PASMC_atorvastatin_rep1 | 28.9 | 45 |
| GSM215312 | PASMC_atorvastatin_rep2 | ||
| GSM215313 | PASMC_atorvastatin_rep3 | 10.6 | 16 |
| GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 30.2 | 46 |
| GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 14.8 | 28 |
| GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 9.2 | 16 |
| GSM215327 | PASMC_SLx2119_rep1 | ||
| GSM215328 | PASMC_SLx2119_rep2 | ||
| GSM215329 | PASMC_SLx2119_rep3 | ||
| GSM215330 | Fibroblasts_vehicle_rep1 | 6.8 | 17 |
| GSM215331 | Fibroblasts_vehicle_rep2 | ||
| GSM215332 | Fibroblasts_vehicle_rep3 | ||
| GSM215333 | Fibroblasts_atorvastatin_rep1 | 5.2 | 14 |
| GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
| GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
| GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 7.7 | 26 |
| GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 19.6 | 52 |
| GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
| GSM215339 | Fibroblasts_SLx2119_rep1 | 0.8 | 2 |
| GSM215340 | Fibroblasts_SLx2119_rep2 | 5.5 | 16 |
| GSM215341 | Fibroblasts_SLx2119_rep3 | 3.5 | 9 |